pharmaceuticals
APAC’s price controls, tendering processes pose risks to pharma firms
APAC’s price controls, tendering processes pose risks to pharma firms
Such practices could impact revenues and market access.
APAC’s HTA adoption to grow amidst infrastructure, talent challenges
Key markets include Indonesia, the Philippines, and Australia.
Oral proteins and peptides market to hit $24b by 2030
Its expansion is attributed to the prevalence of chronic diseases like diabetes.
7MM COPD market to hit $30.2b in 2033
Triple therapy inhalers are expected to account for 11.3% of the total market.
Japan’s 10-year fund to boost pharmaceutical landscape
The country’s ageing population is driving demand for innovative treatments.
Saudi Arabia’s pharmaceutical market to hit $16.7b by 2029
Thanks to rising investments and increased international collaboration.
South Korea, China lead degrader-antibody conjugate development: report
Companies from these countries collectively account for 19 out of 28 assets worldwide.
India’s pharmaceutical market to reach $41.4b by 2029
This expansion is supported by ongoing public sector efforts.
Personalised medicine outsourcing market to reach $223.69b by 2030
One key driver is the need for specialised expertise.
Global transmucosal drugs market to be valued at $28b by 2032
Thanks to the rising prevalence of chronic conditions.
APAC to boost pharmaceutical growth with increased R&D investments
South Korea allocated 5.2% of its GDP to R&D in 2024.
Antibiotics market to grow by $18.22b by 2029
Key drivers include strategic alliances and mergers amongst pharmaceutical firms.
Australia’s pharmaceutical market to see 6% five-year CAGR growth: report
Government measures are expected to challenge pharmaceutical firms.
Biopharmaceutical industry sees mixed performance in 2024: report
Over two-thirds of the top 20 global firms reported a decline in market capitalisation.
Indonesia’s pharma sector to rely on imports despite export boost: report
Imports are forecast to hit $1.6b by 2029, whilst exports are expected to reach $927m.
What’s next for the global heparin market?
It is expected to witness a CAGR of 7.22% through 2028.
UAE pharmaceutical market to be valued at $7.9b by 2029
One driver is the new mandatory health insurance scheme for all private sector employees.